Skip to main content

Market Overview

Why Are Alkermes Shares Trading Lower Today?

Share:
Why Are Alkermes Shares Trading Lower Today?
  • Alkermes plc (NASDAQ: ALKSposted Q3 sales of $294.1 million, up 11% Y/Y, missing the consensus of $301.36 million.
  •  Vivitrol sales increased 11% to $88.8 million, and Aristada sales increased 10% to $68.9 million.
  • Manufacturing and royalty revenues were $136.3 million, compared to $120.4 million a year ago.
  • Total operating expenses increased 14% to $313.8 million.
  • Adjusted net income fell 43% to $23.6 million. Adjusted EPS of $0.14 came above the consensus of $0.06.
  • Alkermes recorded cash, cash equivalents, and total investments of $748.2 million.
  • Alkermes reiterates its financial expectations for 2021 announced in the Q2 earnings release
  • It expects sales of $1.14 billion - $1.18 billion, including Vivitrol sales of $330 million – $345 million and Aristada revenues of $275 million – $290 million. The Company forecasts adjusted EPS of $0.52 – $0.70.
  • Price Action: ALKS shares are down 8.35% at $28.88 during the market session on the last check Wednesday.
 

Related Articles (ALKS)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Guidance Health Care Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com